WASHINGTON, Oct 26 (Reuters) - InterMune Inc. <ITMN> has agreed to pay more than $36.9 million to settle charges of illegally promoting its Actimmune drug that led to the submission of false claims for reimbursement from government health programs, the U.S. Justice Department said on Thursday.
The biopharmaceutical firm was accused of promoting the drug to treat lung scarring despite not being approved by the Food and Drug Administration for that use, and submitting false claims for reimbursement, the Justice Department said.
Actimmune was approved by the FDA for treating immune system disorders. <<